Evidence map›Paper›PMID 42226556›Full record

ArticleJournal of surgical oncology2026

Enhanced Molecular Staging of Pancreatic Cancer Using Methylated DNA Markers in Peritoneal Lavage Fluid.

Krystal Mills, Calise K Berger, William R Taylor, Douglas W Mahoney, Kelli N Burger, Kalika Maheshwari, Benjamin R Kipp, Adriana M Delgado, Karen A Doering, Heather M Streich and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Krystal MillsDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Calise K BergerDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
William R TaylorDivision of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
Douglas W MahoneyDivision of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, Minnesota, USA.
Kelli N BurgerDivision of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, Minnesota, USA.
Kalika MaheshwariDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Benjamin R KippDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Adriana M DelgadoDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Karen A DoeringDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Heather M StreichDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Patrick H FooteDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Sean P ClearyDivision of Hepatobiliary and Pancreas Surgery, Mayo Clinic, Rochester, Minnesota, USA.
Travis E GrotzDivision of Hepatobiliary and Pancreas Surgery, Mayo Clinic, Rochester, Minnesota, USA.ORCID https://orcid.org/0000-0002-7753-097X
Micheal L KendrickDivision of Hepatobiliary and Pancreas Surgery, Mayo Clinic, Rochester, Minnesota, USA.
Rory L SmootDivision of Hepatobiliary and Pancreas Surgery, Mayo Clinic, Rochester, Minnesota, USA.
Patrick P StarlingerDivision of Hepatobiliary and Pancreas Surgery, Mayo Clinic, Rochester, Minnesota, USA.
Cornelius A ThielsDivision of Hepatobiliary and Pancreas Surgery, Mayo Clinic, Rochester, Minnesota, USA.
Mark J TrutyDivision of Hepatobiliary and Pancreas Surgery, Mayo Clinic, Rochester, Minnesota, USA.
Susanne G WarnerDivision of Hepatobiliary and Pancreas Surgery, Mayo Clinic, Rochester, Minnesota, USA.
John B KisielDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Shounak MajumderDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.

Funding

Mayo Clinic Prospective Resource for Biomarker Validation and Early Detection of Pancreatic CancerU01CA210138 · NCI · MAYO CLINIC ROCHESTER · PI Shounak Majumder, Kenneth Zaret · 2016 to 2026
$9.0M
Multi-site Gastrointestinal Cancer Detection by Stool DNA MethylationR37CA214679 · NCI · MAYO CLINIC ROCHESTER · PI KISIEL, JOHN · 2018 to 2024
$2.8M
Centene Foundation (to Dr. Majumder)Exact Sciences (Madison, WI) Provided Critical Assay Reagents R37CA214679Exact Sciences (Madison, WI) Provided Critical Assay Reagents U01CA210138NCI NIH HHS R37 CA214679NCI NIH HHS U01 CA210138
6 · The paper itself

Abstract

BACKGROUND AND

objectivesOccult intra-abdominal metastases are identified in approximately 20% of patients with radiographically localized pancreatic ductal adenocarcinoma (PDAC) through staging laparoscopy, as peritoneal cytology is limited in sensitivity. Methylated DNA markers (MDMs) have demonstrated high diagnostic accuracy for PDAC in tumor tissue, blood, and pancreatic secretions. This study assesses the feasibility and diagnostic performance of MDMs in peritoneal lavage fluid collected during staging laparoscopy, comparing their performance to mutant KRAS (mKRAS) detection.

methodsDNA from peritoneal lavage fluid of PDAC patients was analyzed for mKRAS mutations (codons 12, 13, and 61) using droplet-digital PCR and for 13 MDMs and a reference gene (B3GALT6) using quantitative methylation-specific PCR. An MDM score was generated from the average signal of the 13 MDMs and evaluated for its ability to detect intra-abdominal metastases via receiver operator characteristic (ROC) analysis.

resultsAmong 48 patients, 15 (31%) had intra-abdominal metastases. The MDM score showed 87% sensitivity and 90% specificity (AUC = 0.98), outperforming mKRAS, which showed 40% sensitivity and 85% specificity (AUC = 0.62; p < 0.0001).

conclusionsMDMs in peritoneal lavage fluid may enable highly accurate molecular staging of PDAC and warrant validation in larger studies.

Indexed as

Ascitic FluidBiomarkers, TumorCarcinoma, Pancreatic DuctalDNA MethylationPancreatic NeoplasmsAgedAged, 80 and overFemaleHumansMaleMiddle AgedMutationNeoplasm StagingPeritoneal LavageProto-Oncogene Proteins p21(ras)Biomarkers, TumorKRAS protein, humanProto-Oncogene Proteins p21(ras)methylated DNA markersmutant KRAS (mKRAS)pancreatic ductal adenocarcinomaperitoneal lavage fluidstaging laparoscopy

Identifiers

PMID42226556
PMCPMC13427105

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.